Laurus Labs zooms 128% from March low; hits new high in weak market
Laurus Labs set out an expansion in a quarterly results development for Q2FY27.
· Business Standard Mkts
Laurus Labs Q2 outlook: On the EBITDA front, analysts at Kotak Institutional Equities build in 67% YoY growth to ₹680 crore in Q2FY27 with EBITDA margin expansion of 680 bps to 31.2%.
Key facts
- Period
- Q2FY27
The analysis
Laurus Labs reported ₹680 crore for Q2FY27, with movement of 67%, 128% and 31.2% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +7.2% on the day at ₹2,405.50, and has returned +35.0% over three months. It is trading close to its 52-week high, so expectations were already elevated going in. The pharma & healthcare sector has moved -0.9% over the same period, so Laurus Labs is running 35.9 points ahead of its peers.
For Laurus Labs, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Laurus Labs (LAURUSLABS), in Pharma & Healthcare.
- Over three months: Laurus Labs +35.0% against Pharma & Healthcare -0.9% (35.9 points ahead).
- Trading well above normal today: Laurus Labs at 4.2 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Laurus LabsLAURUSLABS · Pharma & Healthcare | ₹2,405.50 | +7.2% | +21.5% | +35.0% | 0.0% | 4.2× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Laurus Labs
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY
Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses